These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 38284703

  • 1. Impact of 68Ga-PSMA PET/CT on Survival and Management in Prostate Cancer.
    Algın E, Okudan B, Açıkgöz Y, Sayan H, Bal Ö, Seven B.
    Curr Med Imaging; 2024; 20():e15734056276494. PubMed ID: 38284703
    [Abstract] [Full Text] [Related]

  • 2. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
    Rogic I, Golubic AT, Zuvic M, Smitran T, Jukic N, Gamulin M, Kastelan Z, Huic D.
    Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
    [Abstract] [Full Text] [Related]

  • 3. How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses.
    Erdem S, Simsek DH, Degirmenci E, Aydin R, Bagbudar S, Ozluk Y, Sanli Y, Sanli O, Ozcan F.
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [Abstract] [Full Text] [Related]

  • 4. PET/CT With 68Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications.
    Giovacchini G, Giovannini E, Riondato M, Ciarmiello A.
    Curr Radiopharm; 2018 Jan; 11(1):4-13. PubMed ID: 29090673
    [Abstract] [Full Text] [Related]

  • 5. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.
    Zang S, Shao G, Cui C, Li TN, Huang Y, Yao X, Fan Q, Chen Z, Du J, Jia R, Sun H, Hua Z, Tang J, Wang F.
    Oncotarget; 2017 Feb 14; 8(7):12247-12258. PubMed ID: 28103574
    [Abstract] [Full Text] [Related]

  • 6. Diagnostic Accuracy of 68Ga-PSMA PET/CT for Initial Detection in Patients With Suspected Prostate Cancer: A Systematic Review and Meta-Analysis.
    Satapathy S, Singh H, Kumar R, Mittal BR.
    AJR Am J Roentgenol; 2021 Mar 14; 216(3):599-607. PubMed ID: 32755196
    [Abstract] [Full Text] [Related]

  • 7. The influence of 68Ga-prostate-specific membrane antigen PET/computed tomography on prostate cancer staging and planning of definitive radiation therapy.
    Al-Ibraheem A, Abuhijla F, Salah S, Shahait M, Khader J, Mohamad I, Al-Rasheed U, Pomykala KL, Herrmann K, Abu-Hijlih R.
    Nucl Med Commun; 2021 Jul 01; 42(7):811-817. PubMed ID: 33660693
    [Abstract] [Full Text] [Related]

  • 8. Role of 68Ga-PSMA PET/CT parameters in treatment evaluation and survival prediction in prostate cancer patients compared with biochemical response assessment.
    Can C, Gündoğan C, Yildirim OA, Poyraz K, Güzel Y, Kömek H.
    Hell J Nucl Med; 2021 Jul 01; 24(1):25-35. PubMed ID: 33866336
    [Abstract] [Full Text] [Related]

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jul 01; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 10. Primary lymph-node staging with 68Ga-PSMA PET in high-risk prostate cancer: pathologic correlation with extended pelvic lymphadenectomy specimens.
    Corona-Montes VE, González-Cuenca E, Fernández-Noyola G, Olarte-Casas MA, Bobadilla-Salazar D, Medrano-Urtecho HM, Asimakopoulos AD.
    Urol Oncol; 2021 Aug 01; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [Abstract] [Full Text] [Related]

  • 11. Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience.
    Okudan B, Coşkun N, Seven B, Atalay MA, Yildirim A, Görtan FA.
    Nucl Med Commun; 2021 Nov 01; 42(11):1254-1260. PubMed ID: 34284438
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of 68Ga-PSMA PET/CT with volumetric parameters for staging of prostate cancer patients.
    Aksu A, Karahan Şen NP, Tuna EB, Aslan G, Çapa Kaya G.
    Nucl Med Commun; 2021 May 01; 42(5):503-509. PubMed ID: 33560717
    [Abstract] [Full Text] [Related]

  • 13. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
    Kabasakal L, Demirci E, Nematyazar J, Akyel R, Razavi B, Ocak M, Aygun A, Obek C, Kural AR.
    Nucl Med Commun; 2017 Feb 01; 38(2):149-155. PubMed ID: 27893589
    [Abstract] [Full Text] [Related]

  • 14. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
    Barbaud M, Frindel M, Ferrer L, Le Thiec M, Rusu D, Rauscher A, Maucherat B, Baumgartner P, Fleury V, Colombié M, Thierry-Morel A, Kraeber-Bodéré F, Campion L, Rousseau C.
    Prostate; 2019 Apr 01; 79(5):454-461. PubMed ID: 30549066
    [Abstract] [Full Text] [Related]

  • 15. Correlations between whole body volumetric parameters of 68Ga-PSMA PET/CT and biochemical-histopathological parameters in castration-naive and resistant prostate cancer patients.
    Yildirim ÖA, Gündoğan C, Can C, Poyraz K, Erdur E, Kömek H.
    Ann Nucl Med; 2021 May 01; 35(5):540-548. PubMed ID: 33586097
    [Abstract] [Full Text] [Related]

  • 16. 68Ga-PSMA-11 PET imaging in patients with ongoing androgen deprivation therapy for advanced prostate cancer.
    Fassbind S, Ferraro DA, Stelmes JJ, Fankhauser CD, Guckenberger M, Kaufmann PA, Eberli D, Burger IA, Kranzbühler B.
    Ann Nucl Med; 2021 Oct 01; 35(10):1109-1116. PubMed ID: 34185262
    [Abstract] [Full Text] [Related]

  • 17. The superior detection rate of total-body [68Ga]Ga-PSMA-11 PET/CT compared to short axial field-of-view [68Ga]Ga-PSMA-11 PET/CT for early recurrent prostate cancer patients with PSA < 0.2 ng/mL after radical prostatectomy.
    Wang Y, Dong L, Zhao H, Li L, Huang G, Xue W, Liu J, Chen R.
    Eur J Nucl Med Mol Imaging; 2024 Jul 01; 51(8):2484-2494. PubMed ID: 38514483
    [Abstract] [Full Text] [Related]

  • 18. Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study.
    Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, Nickols N, Rettig MB, Reiter RE, Czernin J, Calais J.
    J Nucl Med; 2020 Aug 01; 61(8):1153-1160. PubMed ID: 31924715
    [Abstract] [Full Text] [Related]

  • 19. The meta-analysis of the effect of 68Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan.
    Zhao R, Li Y, Nie L, Qin K, Zhang H, Shi H.
    Medicine (Baltimore); 2021 Apr 16; 100(15):e25417. PubMed ID: 33847640
    [Abstract] [Full Text] [Related]

  • 20. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep 16; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.